Solvonis Therapeutics plc (GB:SVNS)
LSE:SVNS
Want to see GB:SVNS full AI Analyst Report?
Total Valuation
Solvonis Therapeutics has a market cap or net worth of £16.68M. The enterprise value is 15.03M .
Market Cap£16.68M
Enterprise Value15.03M
Share Statistics
Solvonis Therapeutics has 6,806,403,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,806,403,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Solvonis Therapeutics’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is -48.94%.
Return on Equity (ROE)-0.93
Return on Assets (ROA)-0.76
Return on Invested Capital (ROIC)-48.94%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-1.91M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Solvonis Therapeutics is ―. Solvonis Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio2.44
Price to Fair Value2.44
Price to FCF-4.61
Price to Operating Cash Flow-4.01
PEG Ratio0.00
Income Statement
In the last 12 months, Solvonis Therapeutics had revenue of 0.00 and earned -5.74M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit0.00
Operating Income-3.48M
Pretax Income-5.74M
Net Income-5.74M
EBITDA-5.74M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -572.00K and capital expenditures -4.00K, giving a free cash flow of -576.00K billion.
Operating Cash Flow-572.00K
Free Cash Flow-576.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Solvonis Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.83
52-Week Price Change107.69%
50-Day Moving Average0.25
200-Day Moving Average0.28
Relative Strength Index (RSI)47.66
Average Volume (3m)34.43M
Important Dates
Solvonis Therapeutics upcoming earnings date is Sep 24, 2026, Before Open (Not Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateSep 24, 2026
Ex-Dividend Date―
Financial Position
Solvonis Therapeutics as a current ratio of 4.00, with Debt / Equity ratio of 1.21%
Current Ratio4.00
Quick Ratio4.00
Debt to Market Cap<0.01
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Solvonis Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Solvonis Therapeutics EV to EBITDA ratio is -2.34, with an EV/FCF ratio of -4.10.
EV to Sales0.00
EV to EBITDA-2.34
EV to Free Cash Flow-4.10
EV to Operating Cash Flow-4.10
Balance Sheet
Solvonis Therapeutics has £757.00K in cash and marketable securities with £0.00 in debt, giving a net cash position of £757.00K billion.
Cash & Marketable Securities£757.00K
Total Debt£0.00
Net Cash£757.00K
Net Cash Per Share<£0.01
Tangible Book Value Per Share<£0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Solvonis Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―